Dżuma – Rokowania, prognozy i postęp choroby

Dżuma
Rokowania, prognozy i postęp choroby

Dżuma, wywoływana przez Yersinia pestis, charakteryzuje się wysoką śmiertelnością, szczególnie przy opóźnionym leczeniu. Wskaźniki śmiertelności różnią się w zależności od formy klinicznej: dżuma dymienicza bez leczenia ma śmiertelność 30-60%, leczona około 10%; dżuma posocznicowa wykazuje 30-50% śmiertelności mimo antybiotykoterapii, a nieleczona niemal 100%; dżuma płucna jest niemal zawsze śmiertelna bez leczenia (100%), a przy terapii śmiertelność wynosi 30-50%. Wczesne wdrożenie antybiotyków jest kluczowe, zwłaszcza że dżuma płucna może prowadzić do zgonu w ciągu 18-24 godzin od pojawienia się objawów. Stosowane klasy leków to aminoglikozydy, tetracykliny, fluorochinolony, sulfonamidy, fenikole oraz β-laktamy, przy czym zalecana jest monoterapia ze względu na brak dowodów na korzyści terapii skojarzonej.

Prognoza Dżumy (przewidywanie wyników leczenia)

Wskaźniki śmiertelności w zależności od postaci dżumy
Znaczenie wczesnej interwencji terapeutycznej
Skuteczność dostępnych metod leczenia
Czynniki wpływające na prognozę i przewidywanie epidemii
Globalne perspektywy i obecna sytuacja
Indywidualne rokowanie pacjentów
Kolejne rozdziały

Prognoza Dżumy (przewidywanie wyników leczenia)

Dżuma jest ciężką chorobą zakaźną wywoływaną przez bakterię Yersinia pestis, która może prowadzić do wysokiej śmiertelności, szczególnie w przypadku opóźnionego rozpoczęcia leczenia. Rokowanie pacjentów z dżumą zależy od wielu czynników, w tym formy klinicznej zakażenia, czasu rozpoczęcia terapii oraz dostępu do odpowiednich antybiotyków.¹²

Wskaźniki śmiertelności w zależności od postaci dżumy

Wskaźniki śmiertelności różnią się znacząco w zależności od formy klinicznej dżumy:¹²

Dżuma dymienicza – wskaźnik śmiertelności wynosi 30-60% bez leczenia; przy odpowiednim leczeniu antybiotykami śmiertelność spada do około 10%
Dżuma posocznicowa – śmiertelność 30-50% nawet przy zastosowaniu antybiotykoterapii, a nieleczona jest prawie zawsze śmiertelna (70-100%)
Dżuma płucna – nieleczona jest niemal zawsze śmiertelna (100%), a nawet przy leczeniu śmiertelność wynosi 30-50%

¹²³

Według danych z USA, ogólny wskaźnik śmiertelności dla wszystkich postaci dżumy wynosi około 11%.¹

Znaczenie wczesnej interwencji terapeutycznej

Wczesne rozpoczęcie antybiotykoterapii ma kluczowe znaczenie dla poprawy rokowania pacjentów z dżumą:¹²

Dżuma płucna może być śmiertelna w ciągu 18-24 godzin od wystąpienia objawów, jeśli nie zostanie podjęte leczenie
Wczesne podanie antybiotyków skutecznie leczy chorobę i znacząco zmniejsza ryzyko powikłań
Profilaktyczne zastosowanie antybiotyków po potencjalnym narażeniu może chronić osoby przed rozwojem dżumy płucnej

¹²³

W przypadku dżumy posocznicowej szybkie postawienie diagnozy jest utrudnione ze względu na niespecyficzne objawy, co może opóźniać wdrożenie odpowiedniego leczenia i pogarszać rokowanie.¹

Skuteczność dostępnych metod leczenia

Wprowadzenie antybiotyków znacząco poprawiło rokowanie pacjentów z dżumą. Obecnie stosowane są różne klasy antybiotyków:¹²

Mimo dostępności skutecznych antybiotyków, wciąż istnieją ograniczenia w prognozie wyników leczenia:¹²

Brak standaryzacji w badaniach przedklinicznych
Sprzeczne dane z raportów przypadków
Niewielka liczba przeprowadzonych badań klinicznych
Różnice w czasie rozpoczęcia leczenia, dawkach i schematach dawkowania

¹²³

Obecnie zalecana jest monoterapia, gdyż leczenie skojarzone nie wykazało dodatkowych korzyści w badaniach przedklinicznych ani w raportach przypadków.¹

Czynniki wpływające na prognozę i przewidywanie epidemii

Poza czynnikami związanymi z samą terapią, na rokowanie w skali populacyjnej wpływają również inne elementy:¹²

Czynniki środowiskowe i klimatyczne

Badania wykazały, że występowanie dżumy jest bezpośrednio związane z cechami środowiskowymi w skali krajobrazu, co umożliwia przewidywanie obszarów ryzyka:¹²

Wpływ opadów na występowanie dżumy u świstaków wykazuje zależność od gęstości populacji
Wpływ temperatury na występowanie dżumy jest zależny od położenia geograficznego
Modele statystyczne wskazują na nieliniowy wpływ gęstości populacji nosicieli i indeksu pcheł na występowanie dżumy

Modelowanie środowiskowe pozwoliło na opracowanie map ryzyka dżumy, które z powodzeniem przewidują znane ogniska w regionie Afryki Wschodniej. Prognozy wskazują, że tylko 15,5% (31 997 km²) tego obszaru jest odpowiednie dla transmisji dżumy.¹²

Modelowanie prognostyczne i badania nad dżumą

Rozwój modeli badawczych ma kluczowe znaczenie dla zrozumienia patogenezy dżumy oraz opracowania nowych metod terapeutycznych:¹

Model mysi służy jako narzędzie do zrozumienia czynników gospodarza, które mogą przyczyniać się do odporności na zakażenie Y. pestis
Kompleksowe zrozumienie interakcji między dżumą a jej żywicielami będzie wymagało danych zebranych z wielu modeli
Dalsze scharakteryzowanie patogenezy dżumy i odpowiedzi immunologicznej w tych modelach będzie ważne dla zrozumienia korelacji ochrony, które można zastosować do przewidywania skuteczności u ludzi

Globalne perspektywy i obecna sytuacja

Mimo że dżuma jest często postrzegana jako choroba historyczna, nadal stanowi problem zdrowia publicznego na skalę globalną:¹²

Światowa Organizacja Zdrowia otrzymuje rocznie raporty o 1000-2000 przypadkach dżumy
Częstość występowania dżumy wzrosła w Amerykach, Azji i Afryce w związku z szybką globalizacją i zmianami klimatu
Izolacja szczepów Y. pestis opornych na antybiotyki zwiększa wysiłki na rzecz zrozumienia patogenezy dżumy i opracowania nowych metod terapeutycznych

¹²³

Obawy dotyczące potencjalnego wykorzystania Y. pestis jako broni biologicznej dodatkowo stymulują badania nad nowymi metodami terapeutycznymi i szczepionkami, które mogłyby zapewnić ochronę w przypadku ataku biologicznego z wykorzystaniem tej bakterii.¹

Indywidualne rokowanie pacjentów

W przypadku indywidualnych pacjentów, którzy przebyli dżumę i zostali odpowiednio leczeni, rokowanie jest bardzo dobre.¹ Jednak należy pamiętać, że nieleczona dżuma może być śmiertelna.¹²

Podsumowując, rokowanie w dżumie zależy od wielu czynników, ale najważniejszym z nich pozostaje wczesna diagnoza i szybkie wdrożenie odpowiedniej antybiotykoterapii. Współczesne metody leczenia znacząco poprawiły wyniki terapii w porównaniu do ery przed wprowadzeniem antybiotyków, choć wciąż istnieją wyzwania związane z optymalizacją schematów leczenia i prognozowaniem przebiegu choroby.¹²³

Kolejne rozdziały

Zapraszamy do dalszego czytania naszego leksykonu.

Wybierz kolejny rozdział z menu poniżej, aby otworzyć nową podstronę kompedium wiedzy i uzyskać szczegółowe informację o leku, substancji lub chorobie.

Materiały źródłowe

#1
https://www.who.int/news-room/fact-sheets/detail/plague
Plague can be a very severe disease in people, with a case-fatality ratio of 30% to 60% for the bubonic type, and is always fatal for the pneumonic kind when left untreated. […] Plague is a very severe disease in people, particularly in its septicaemic (systemic infection caused by circulating bacteria in bloodstream) and pneumonic forms, with a case-fatality ratio of 30% to 100% if left untreated. The pneumonic form is invariably fatal unless treated early. […] Untreated pneumonic plague can be rapidly fatal, so early diagnosis and treatment is essential for survival and reduction of complications. […] Pneumonic plague can be fatal within 18 to 24 hours of disease onset if left untreated, but common antibiotics for enterobacteria (gram negative rods) can effectively cure the disease if they are delivered early.
#1 Plague – Symptoms and causes – Mayo Clinic
https://www.mayoclinic.org/diseases-conditions/plague/symptoms-causes/syc-20351291
Plague usually can be treated with antibiotics. If not treated, the illness is often deadly. […] The risk of death in people with all types of plague in the United States is around 11%. […] Most people with bubonic plague survive with prompt diagnosis and treatment. Death is more likely with septicemic plague because it is difficult to diagnose and worsens rapidly. Treatment may unintentionally be delayed. […] Pneumonic plague is severe and worsens rapidly. Risk of death is high if treatment doesn’t begin within 24 hours after symptoms start.
#1 Antibiotic Therapy of Plague: A Review
https://www.mdpi.com/2218-273X/11/5/724
The premises of antibiotic therapy of infectious diseases go back a long way. […] However, early administration remains essential. […] Even when antibiotics known to be effective are given, patients who develop the bubonic form of plague are most likely to survive: after treatment with antibiotics, around 10% of patients with bubonic plague and 30% to 50% of patients with pneumonic or septicemic plague will nevertheless die. […] The clinical data indicate that many classes of antibiotics (i.e., aminoglycosides, tetracyclines, fluoroquinolones, sulfonamides, phenicols, and Î²-lactams) have been administered to patients with the different forms of plague. […] The analysis of case report data showed that patients (i) are not necessarily treated at the same time after infection, (ii) do not necessarily receive the same drug, as a function of their symptoms, and (iii) have different dose levels and dosing frequencies even when the same drug is administered.
#1 Antibiotic Therapy of Plague: A Review
https://www.mdpi.com/2218-273X/11/5/724
Plagueâa deadly disease caused by the bacterium Yersinia pestisâis still an international public health concern. […] Early antibiotic therapy is essential for countering the disease. […] However, some discrepancies have been reported. […] Hence, health authorities have approved and recommended several drugs for prophylactic or curative use. […] Only monotherapy is currently recommended; combination therapy has not shown any benefits in preclinical studies or case reports. […] It is difficult to know which of the currently available treatments or therapeutics in development will be most effective for a given form of plague. […] This is due to the lack of standardization in preclinical studies, conflicting data from case reports, and the small number of clinical trials performed to date.
#1 Predicting Potential Risk Areas of Human Plague for the Western Usambara Mountains, Lushoto District, Tanzania
https://pmc.ncbi.nlm.nih.gov/articles/PMC2829916/
A natural focus of plague exists in the Western Usambara Mountains of Tanzania. […] Our analyses indicate that plague occurrence is related directly to landscape-scale environmental features, yielding a predictive understanding of one set of environmental factors affecting plague transmission in East Africa. […] Projections of these models across broader regions predict only 15.5% (under a majority-rule threshold) or 31,997 km2 of East Africa as suitable for plague transmission, but they successfully anticipate most known foci in the region, making possible the development of a risk map of plague. […] In this study, we aim to explore the geographic distribution and coarse-resolution ecology of human plague in Lushoto District of Tanzania, identify environmental conditions correlated with human-plague occurrences in Lushoto, reflect on predictability of plague transmission in the region, and finally, extend our local Lushoto model across East Africa.
#1 Climate-driven marmot-plague dynamics in Mongolia and China | Scientific Reports
https://www.nature.com/articles/s41598-023-38966-1
The incidence of plague has rebounded in the Americas, Asia, and Africa alongside rapid globalization and climate change. […] Our results suggested a density-dependent effect of precipitation and a geographic location-dependent effect of temperature on marmot plague. […] The statistical model results indicated a nonlinear effect of marmot density and the flea index on marmot plague occurrence, with an upward trend followed by a flattened trend. […] With regard to precipitation, a significant effect on marmot plague was observed in almost all models. […] This analysis revealed different interaction curves for precipitation and plague under two different regimes of marmot density. […] Our final model involves the explicit density of an animal reservoir and showed the interaction effect of climatic covariates and marmot density on the occurrence of plague. […] Our study validates the threshold theory in plague transmission not only in the great gerbil populations in Kazakhstan but also in marmot populations in China and Mongolia.
#1 Model Systems to Study Plague Pathogenesis and Develop New Therapeutics
https://pmc.ncbi.nlm.nih.gov/articles/PMC3109633/
The mouse model has also served as a tool to begin to understand host determinants that may contribute to resistance to Y. pestis infection. […] The advantages of the mouse model to study pathogenesis also apply to its use in testing potential plague therapeutics. […] A comprehensive understanding of the interactions between plague and its hosts will likely require data gathered from multiple models. As new anti-plague prophylactic and therapeutic candidates are developed, further characterization of plague pathogenesis and immune responses in these models will be important to understand correlates of protection that can be applied toward predicting success in humans.
#1 Yersinia pestis – Wikipedia
https://en.wikipedia.org/wiki/Yersinia_pestis
Between one thousand and two thousand cases of the plague are still reported to the World Health Organization every year. […] With proper antibiotic treatment, the prognosis for victims is much better than before antibiotics were developed.
#1 Model Systems to Study Plague Pathogenesis and Develop New Therapeutics
https://pmc.ncbi.nlm.nih.gov/articles/PMC3109633/
The Gram negative bacterium Yersinia pestis can infect humans by multiple routes to cause plague. […] Plague infection rapidly progresses and is associated with a high mortality rate in untreated individuals (70100%). Successful treatment of infection is greatly increased with early detection. […] While plague has been considered a historic disease, concerns about the use of Y. pestis as a biological weapon and isolation of antibiotic resistant Y. pestis strains from nature have increased efforts to understand plague pathogenesis and develop novel therapeutics. […] Prophylactic antibiotic treatment after a possible exposure can protect individuals from developing pneumonic plague, but new therapeutics and vaccines are needed to ensure protection in the event of a biological attack with weaponized Y. pestis.
#1 Bubonic Plague (Black Death): What Is It, Symptoms, Treatment
https://my.clevelandclinic.org/health/diseases/21590-bubonic-plague
If youve had bubonic plague and been treated for it, your outlook is very good. […] However, untreated bubonic plague can be fatal.
#2 Model Systems to Study Plague Pathogenesis and Develop New Therapeutics
https://pmc.ncbi.nlm.nih.gov/articles/PMC3109633/
The Gram negative bacterium Yersinia pestis can infect humans by multiple routes to cause plague. […] Plague infection rapidly progresses and is associated with a high mortality rate in untreated individuals (70100%). Successful treatment of infection is greatly increased with early detection. […] While plague has been considered a historic disease, concerns about the use of Y. pestis as a biological weapon and isolation of antibiotic resistant Y. pestis strains from nature have increased efforts to understand plague pathogenesis and develop novel therapeutics. […] Prophylactic antibiotic treatment after a possible exposure can protect individuals from developing pneumonic plague, but new therapeutics and vaccines are needed to ensure protection in the event of a biological attack with weaponized Y. pestis.
#2 Antibiotic Therapy of Plague: A Review
https://www.mdpi.com/2218-273X/11/5/724
The premises of antibiotic therapy of infectious diseases go back a long way. […] However, early administration remains essential. […] Even when antibiotics known to be effective are given, patients who develop the bubonic form of plague are most likely to survive: after treatment with antibiotics, around 10% of patients with bubonic plague and 30% to 50% of patients with pneumonic or septicemic plague will nevertheless die. […] The clinical data indicate that many classes of antibiotics (i.e., aminoglycosides, tetracyclines, fluoroquinolones, sulfonamides, phenicols, and Î²-lactams) have been administered to patients with the different forms of plague. […] The analysis of case report data showed that patients (i) are not necessarily treated at the same time after infection, (ii) do not necessarily receive the same drug, as a function of their symptoms, and (iii) have different dose levels and dosing frequencies even when the same drug is administered.
#2 Antibiotic Therapy of Plague: A Review
https://www.mdpi.com/2218-273X/11/5/724
Plagueâa deadly disease caused by the bacterium Yersinia pestisâis still an international public health concern. […] Early antibiotic therapy is essential for countering the disease. […] However, some discrepancies have been reported. […] Hence, health authorities have approved and recommended several drugs for prophylactic or curative use. […] Only monotherapy is currently recommended; combination therapy has not shown any benefits in preclinical studies or case reports. […] It is difficult to know which of the currently available treatments or therapeutics in development will be most effective for a given form of plague. […] This is due to the lack of standardization in preclinical studies, conflicting data from case reports, and the small number of clinical trials performed to date.
#2 Yersinia pestis – Wikipedia
https://en.wikipedia.org/wiki/Yersinia_pestis
Between one thousand and two thousand cases of the plague are still reported to the World Health Organization every year. […] With proper antibiotic treatment, the prognosis for victims is much better than before antibiotics were developed.
#2 Antibiotic Therapy of Plague: A Review
https://www.mdpi.com/2218-273X/11/5/724
These differences result in significant bias in selecting the most effective treatment and emphasize the importance of performing randomized clinical trials. […] In conclusion, the current guidelines on the treatment of plague are based on preclinical and clinical data (which are not fully reliable) and on the availability of antimicrobial drugs in the country concerned. […] The data obtained in vitro and from animal models, case reports and the few published clinical trials show that several treatments approved by the health authorities have prophylactic or therapeutic activity against plague in humans. […] However, it is difficult to predict which treatments will be most effective for each of the different forms of plague.
#2 Climate-driven marmot-plague dynamics in Mongolia and China | Scientific Reports
https://www.nature.com/articles/s41598-023-38966-1
The incidence of plague has rebounded in the Americas, Asia, and Africa alongside rapid globalization and climate change. […] Our results suggested a density-dependent effect of precipitation and a geographic location-dependent effect of temperature on marmot plague. […] The statistical model results indicated a nonlinear effect of marmot density and the flea index on marmot plague occurrence, with an upward trend followed by a flattened trend. […] With regard to precipitation, a significant effect on marmot plague was observed in almost all models. […] This analysis revealed different interaction curves for precipitation and plague under two different regimes of marmot density. […] Our final model involves the explicit density of an animal reservoir and showed the interaction effect of climatic covariates and marmot density on the occurrence of plague. […] Our study validates the threshold theory in plague transmission not only in the great gerbil populations in Kazakhstan but also in marmot populations in China and Mongolia.
#2 Predicting Potential Risk Areas of Human Plague for the Western Usambara Mountains, Lushoto District, Tanzania
https://pmc.ncbi.nlm.nih.gov/articles/PMC2829916/
To test the performance of our best-performing Lushoto model in predicting potential for plague transmission across broader areas, locations of known human-plague occurrences between 1970 and 2008 in Tanzania, Kenya, Uganda, and the Democratic Republic of the Congo (DRC) were compiled through an extensive literature search. […] We evaluated the predicted distributional area for plague based on the independent set of observed plague occurrences across Tanzania, Kenya, Uganda, and DRC described above. […] To produce a plague-risk map for East Africa, we constructed a new ENM using the set of uncorrelated environmental coverages with the best subset of Lushoto occurrence points and the six locations from surrounding areas to which geographic coordinates were assigned. […] We chose our best model based on a balance between omission and commission rates. […] Our main conclusion is that the typical focality of plague, observed in East Africa, can indeed be predicted using 250-m resolution satellite imagery.
#2 Plague – Symptoms and causes – Mayo Clinic
https://www.mayoclinic.org/diseases-conditions/plague/symptoms-causes/syc-20351291
Plague usually can be treated with antibiotics. If not treated, the illness is often deadly. […] The risk of death in people with all types of plague in the United States is around 11%. […] Most people with bubonic plague survive with prompt diagnosis and treatment. Death is more likely with septicemic plague because it is difficult to diagnose and worsens rapidly. Treatment may unintentionally be delayed. […] Pneumonic plague is severe and worsens rapidly. Risk of death is high if treatment doesn’t begin within 24 hours after symptoms start.
#3 Model Systems to Study Plague Pathogenesis and Develop New Therapeutics
https://pmc.ncbi.nlm.nih.gov/articles/PMC3109633/
The Gram negative bacterium Yersinia pestis can infect humans by multiple routes to cause plague. […] Plague infection rapidly progresses and is associated with a high mortality rate in untreated individuals (70100%). Successful treatment of infection is greatly increased with early detection. […] While plague has been considered a historic disease, concerns about the use of Y. pestis as a biological weapon and isolation of antibiotic resistant Y. pestis strains from nature have increased efforts to understand plague pathogenesis and develop novel therapeutics. […] Prophylactic antibiotic treatment after a possible exposure can protect individuals from developing pneumonic plague, but new therapeutics and vaccines are needed to ensure protection in the event of a biological attack with weaponized Y. pestis.
#3 Antibiotic Therapy of Plague: A Review
https://www.mdpi.com/2218-273X/11/5/724
Plagueâa deadly disease caused by the bacterium Yersinia pestisâis still an international public health concern. […] Early antibiotic therapy is essential for countering the disease. […] However, some discrepancies have been reported. […] Hence, health authorities have approved and recommended several drugs for prophylactic or curative use. […] Only monotherapy is currently recommended; combination therapy has not shown any benefits in preclinical studies or case reports. […] It is difficult to know which of the currently available treatments or therapeutics in development will be most effective for a given form of plague. […] This is due to the lack of standardization in preclinical studies, conflicting data from case reports, and the small number of clinical trials performed to date.
#3 Antibiotic Therapy of Plague: A Review
https://www.mdpi.com/2218-273X/11/5/724
These differences result in significant bias in selecting the most effective treatment and emphasize the importance of performing randomized clinical trials. […] In conclusion, the current guidelines on the treatment of plague are based on preclinical and clinical data (which are not fully reliable) and on the availability of antimicrobial drugs in the country concerned. […] The data obtained in vitro and from animal models, case reports and the few published clinical trials show that several treatments approved by the health authorities have prophylactic or therapeutic activity against plague in humans. […] However, it is difficult to predict which treatments will be most effective for each of the different forms of plague.
#3 Plague – Symptoms and causes – Mayo Clinic
https://www.mayoclinic.org/diseases-conditions/plague/symptoms-causes/syc-20351291
Plague usually can be treated with antibiotics. If not treated, the illness is often deadly. […] The risk of death in people with all types of plague in the United States is around 11%. […] Most people with bubonic plague survive with prompt diagnosis and treatment. Death is more likely with septicemic plague because it is difficult to diagnose and worsens rapidly. Treatment may unintentionally be delayed. […] Pneumonic plague is severe and worsens rapidly. Risk of death is high if treatment doesn’t begin within 24 hours after symptoms start.